Search clinical trials for: melanoma helper peptide vaccine

Total 329 results

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Stage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64)

Melanoma

United States
Craig L Slingluff, Jr

Completed

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39)

Melanoma

United States
Robert Ferris
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Gitte Kronborg
Rigshospitalet, Denmark; Hvidovre University Hospital; Statens Serum Institut; Ministry...

Completed

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection (HIV-VAC)

HIV INFECTIONS

Denmark
National Liver Institute, Egypt

Unknown

Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)

Vaccine Overdose of Undetermined Intent

Egypt
National Cancer Institute (NCI)

Completed

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Active, not recruiting

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

Melanoma | Ocular Melanoma | Uveal Melanoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Nonneoplastic Condition

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
University of Maryland Greenebaum Cancer Center
National Cancer Institute (NCI)

Completed

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
AVAX Technologies

Completed

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

Melanoma

United States
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
COL George Peoples, MD, FACS

Completed

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Michael Morse, MD
Immunotope

Completed

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Epithelial Ovarian, Tubal or Peritoneal Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University Hospital Tuebingen

Not yet recruiting

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients (AML-VAC-XS15)

Acute Myeloid Leukemia, Adult
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
GlaxoSmithKline

Completed

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

Herpes Simplex

United States, Belgium, Canada
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN)

Malaria

Tanzania
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (MSP3LSP)

Malaria

Burkina Faso
Craig L Slingluff, Jr
Cancer Research Institute, New York City; Ludwig Institute for Cancer Research

Terminated

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP)

Melanoma

United States
University of Rochester
GlaxoSmithKline

Completed

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Chronic Lymphocytic Leukemia (CLL) | Waldenstrom Macroglobulinemia (WM)

United States
GlaxoSmithKline

Completed

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Herpes Zoster

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

NSCLC Stage IV | ALK Fusion Protein Expression

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

Herpes Zoster

Russian Federation, Canada
Beijing Luzhu Biotechnology Co., Ltd.

Recruiting

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Herpes Zoster | Vaccine-Preventable Diseases

China

Search clinical trials for: melanoma helper peptide vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations